Qiagen and CellBxHealth announced a co‑marketing partnership on November 18, 2025, that will allow Qiagen to bundle its Parsortix circulating‑tumor‑cell (CTC) platform with its own PCR, digital PCR and next‑generation sequencing technologies. The agreement gives Qiagen the right to sign contracts directly with pharmaceutical partners and to outsource CTC enrichment and analysis to CellBxHealth, while the two companies will jointly promote their technologies and explore integration of Qiagen’s automated DNA extraction and sequencing systems into the Parsortix workflow.
The partnership is a strategic fit for Qiagen’s "Sample to Insight" strategy, which seeks to provide end‑to‑end solutions from sample preparation to data analysis. By adding CellBxHealth’s microfluidic‑based Parsortix platform—known for capturing intact CTCs without relying on surface markers—Qiagen can offer a more comprehensive liquid‑biopsy workflow that supports biomarker discovery and early companion‑diagnostic development in oncology drug programs. The collaboration also establishes a framework for a future co‑developed diagnostic product, positioning both companies to accelerate the adoption of liquid‑biopsy technologies in clinical and research settings.
Liquid‑biopsy and CTC isolation represent a rapidly growing segment of the oncology diagnostics market, with multiple players competing to provide faster, less invasive alternatives to tissue biopsies. Qiagen’s move to integrate Parsortix expands its footprint in this high‑growth area and strengthens its competitive position against other CTC platforms such as CellSearch. The partnership also taps into the broader trend of precision oncology, where real‑time monitoring of tumor dynamics can inform treatment decisions and improve patient outcomes.
From a business perspective, the alliance aligns with Qiagen’s recent financial performance, which saw a 6% year‑over‑year revenue increase and a 29.6% adjusted operating income margin in Q3 2025. The company’s management has emphasized continued focus on cost discipline and strategic investments in high‑return verticals. CEO Thierry Bernard highlighted the partnership as a key element of Qiagen’s growth strategy, noting that the combined platform will “enhance our sample‑to‑insight offering and accelerate biomarker discovery.” CFO Roland Sackers added that the collaboration supports Qiagen’s goal of maintaining a 31% EBIT margin by 2028 and reinforces the company’s ability to generate strong cash flow while pursuing high‑impact innovations.
The partnership also signals Qiagen’s confidence in the long‑term trajectory of liquid‑biopsy technologies. By leveraging CellBxHealth’s expertise in CTC enrichment and Qiagen’s robust sequencing and data‑analysis capabilities, the alliance is poised to deliver a more powerful diagnostic tool that can be integrated into pharmaceutical development pipelines, potentially shortening the time to market for companion diagnostics and improving the efficiency of oncology drug development.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.